發(fā)布時(shí)間：2018-05-25 23:05

  本文選題：中醫(yī)藥 + 知識(shí)產(chǎn)權(quán)保護(hù)��； 參考：《南京中醫(yī)藥大學(xué)》2015年碩士論文

【摘要】：目前,西方發(fā)達(dá)國(guó)家正逐步將中醫(yī)藥推為“公共知識(shí)”,而不是將其作為知識(shí)產(chǎn)權(quán)的一種保護(hù)對(duì)象,并正在對(duì)其進(jìn)行著無償商業(yè)性開發(fā)和盈利,這無疑加速了我國(guó)中醫(yī)藥知識(shí)產(chǎn)權(quán)的流失。中醫(yī)藥知識(shí)產(chǎn)權(quán)的流失不僅會(huì)損害本土中醫(yī)藥企業(yè)及國(guó)家的整體利益,還將阻礙本土中醫(yī)藥品牌及產(chǎn)業(yè)的可持續(xù)發(fā)展,進(jìn)而對(duì)我國(guó)中醫(yī)藥產(chǎn)業(yè)的國(guó)際化進(jìn)程造成威脅。因此,加強(qiáng)我國(guó)中醫(yī)藥知識(shí)產(chǎn)權(quán)保護(hù),實(shí)現(xiàn)并維護(hù)好我國(guó)傳統(tǒng)中醫(yī)藥知識(shí)的利益,對(duì)中醫(yī)藥產(chǎn)業(yè)安全具有深遠(yuǎn)影響。基于知識(shí)產(chǎn)權(quán)保護(hù),探索我國(guó)的中醫(yī)藥產(chǎn)業(yè)安全,不僅具有理論價(jià)值,更具有重要的現(xiàn)實(shí)意義。本研究以中醫(yī)藥知識(shí)產(chǎn)權(quán)保護(hù)為視角,探討中醫(yī)藥產(chǎn)業(yè)安全問題,所作研究主要包括以下幾個(gè)方面：(1)通過大量的文獻(xiàn)檢索和閱讀,在對(duì)影響中醫(yī)藥產(chǎn)業(yè)安全的知識(shí)產(chǎn)權(quán)要素進(jìn)行分析的基礎(chǔ)上,進(jìn)行指標(biāo)體系的初步設(shè)計(jì),將中醫(yī)藥產(chǎn)業(yè)知識(shí)產(chǎn)權(quán)保護(hù)水平從產(chǎn)業(yè)國(guó)內(nèi)環(huán)境中分離出來,并將其作為目前我國(guó)中醫(yī)藥知識(shí)產(chǎn)權(quán)保護(hù)的制度環(huán)境重點(diǎn)考察。(2)針對(duì)初建的指標(biāo)體系進(jìn)行第一輪專家咨詢,通過統(tǒng)計(jì)分析對(duì)指標(biāo)體系進(jìn)行篩選,并通過因子分析對(duì)篩選后的指標(biāo)體系進(jìn)行結(jié)構(gòu)檢驗(yàn),最終確立了包含中醫(yī)藥產(chǎn)業(yè)知識(shí)產(chǎn)權(quán)保護(hù)水平、知識(shí)產(chǎn)權(quán)保護(hù)背景下中醫(yī)藥產(chǎn)業(yè)自主創(chuàng)新水平、中醫(yī)藥產(chǎn)業(yè)國(guó)內(nèi)環(huán)境及知識(shí)產(chǎn)權(quán)保護(hù)背景下中醫(yī)藥產(chǎn)業(yè)競(jìng)爭(zhēng)力四個(gè)維度的評(píng)價(jià)指標(biāo)體系。(3)針對(duì)指標(biāo)權(quán)重進(jìn)行第二輪專家咨詢,利用層次分析法,確定指標(biāo)權(quán)重。(4)在對(duì)因素層進(jìn)行現(xiàn)狀分析的基礎(chǔ)上進(jìn)行第三輪專家咨詢,以獲取專家對(duì)于各指標(biāo)的評(píng)價(jià)結(jié)果及評(píng)價(jià)值,并利用物元可拓模型對(duì)中醫(yī)藥產(chǎn)業(yè)安全進(jìn)行多級(jí)可拓評(píng)價(jià)。研究發(fā)現(xiàn),中醫(yī)藥產(chǎn)業(yè)國(guó)內(nèi)環(huán)境處于基本安全狀態(tài),而知識(shí)產(chǎn)權(quán)保護(hù)水平、知識(shí)產(chǎn)權(quán)保護(hù)背景下自主創(chuàng)新水平和競(jìng)爭(zhēng)力均處于不安全狀態(tài)。從產(chǎn)業(yè)整體來看,中醫(yī)藥產(chǎn)業(yè)整體呈現(xiàn)出不安全狀態(tài)。最后,基于研究結(jié)果,圍繞知識(shí)產(chǎn)權(quán)保護(hù)提出了相關(guān)對(duì)策和建議。
[Abstract]:At present, the western developed countries are gradually pushing traditional Chinese medicine into "public knowledge", instead of taking it as a protection object of intellectual property, and is carrying out unpaid commercial exploitation and profit. This undoubtedly accelerates the loss of intellectual property rights of Chinese medicine. The loss of intellectual property rights of traditional Chinese Medicine will not only damage local traditional Chinese medicine enterprises. The overall interests of the industry and the state will also impede the sustainable development of local traditional Chinese medicine brand and industry, and then threaten the internationalization of Chinese traditional Chinese medicine industry. Therefore, strengthening the protection of intellectual property rights of Chinese medicine, realizing and maintaining the interests of the knowledge of traditional Chinese medicine, has far-reaching influence on the safety of traditional Chinese medicine industry. In the protection of intellectual property, the exploration of the safety of Chinese medicine industry is not only of theoretical value but also of great practical significance. In this study, the problem of the safety of traditional Chinese medicine industry is discussed with the protection of intellectual property rights of traditional Chinese medicine as the angle of view. The research mainly includes the following aspects: (1) through a large number of literature retrieval and reading, the impact of the study is on the influence of Chinese medicine. On the basis of the analysis of the intellectual property factors of the medical industry safety, the preliminary design of the index system is carried out, the intellectual property protection level of the Chinese medicine industry is separated from the domestic environment, and the system environment of the intellectual property protection of Chinese medicine is reviewed. (2) the first built index system is carried out. A round of expert consultation, through the statistical analysis of the index system screening, and through the factor analysis of the selected index system to test the structure, and finally established the level of intellectual property protection including the traditional Chinese medicine industry, the level of independent innovation of traditional Chinese medicine industry under the background of intellectual property protection, the domestic environment of traditional Chinese medicine industry and intellectual property protection. The evaluation index system of the four dimensions of the competitiveness of Chinese medicine industry under the background of protecting the background. (3) second rounds of expert consultation on the index weight and the use of analytic hierarchy process (AHP) to determine the weight of the index. (4) a third round of expert consultation is carried out on the basis of the status analysis of the factor layer, in order to obtain the evaluation results and evaluation values of the experts on each index, and The multilevel extension evaluation of traditional Chinese medicine industry safety is carried out by the matter element extension model. It is found that the domestic environment of the Chinese medicine industry is in the basic state of security, while the level of intellectual property protection and the independent innovation level and competitiveness under the background of intellectual property protection are insecure. From the whole industry, the whole Chinese medicine industry presents Finally, based on the research results, relevant countermeasures and suggestions are put forward around the protection of intellectual property rights.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：F426.72;F204;R288

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 尹莉娟;趙銀德;張立強(qiáng);許鮮欣;;我國(guó)中藥材出口競(jìng)爭(zhēng)力分析及策略[J];安徽農(nóng)業(yè)科學(xué);2010年25期

2 張董;;知識(shí)產(chǎn)權(quán)對(duì)我國(guó)中醫(yī)藥產(chǎn)業(yè)國(guó)際化影響的實(shí)證分析[J];經(jīng)營(yíng)管理者;2009年08期

3 王鍵;黃輝;;中醫(yī)學(xué)與中華傳統(tǒng)文化(一)[J];中醫(yī)藥臨床雜志;2011年01期

4 林維勇;張小平;王喜賓;;基于灰關(guān)聯(lián)分析構(gòu)建中藥現(xiàn)代化產(chǎn)業(yè)績(jī)效評(píng)估指標(biāo)體系[J];貴州大學(xué)學(xué)報(bào)(自然科學(xué)版);2012年04期

5 王治彪;;中醫(yī)藥產(chǎn)業(yè)安全的思考[J];北京理工大學(xué)學(xué)報(bào)(社會(huì)科學(xué)版);2013年06期

6 林仲源;秦藝蓉;蔡鴻;;基于熵值法的我國(guó)中醫(yī)藥產(chǎn)業(yè)競(jìng)爭(zhēng)力實(shí)證研究[J];產(chǎn)業(yè)與科技論壇;2014年03期

7 紀(jì)媛媛;;從知識(shí)產(chǎn)權(quán)角度淺談拜耳收購中藥企業(yè)的產(chǎn)業(yè)安全思考[J];中國(guó)發(fā)明與專利;2015年02期

8 何維達(dá);李冬梅;;我國(guó)產(chǎn)業(yè)安全理論研究綜述[J];經(jīng)濟(jì)縱橫;2006年08期

9 索貴彬;趙國(guó)杰;;基于灰色可拓物元模型的企業(yè)技術(shù)創(chuàng)新風(fēng)險(xiǎn)度量研究[J];科學(xué)管理研究;2008年01期

10 王立平;劉平;呂波;張新明;周建仁;;我國(guó)農(nóng)林植物新品種保護(hù)現(xiàn)狀與展望[J];中國(guó)農(nóng)業(yè)科技導(dǎo)報(bào);2010年06期

相關(guān)重要報(bào)紙文章 前1條

1 本報(bào)評(píng)論員 吳瀟湘;[N];中國(guó)中醫(yī)藥報(bào);2013年

相關(guān)博士學(xué)位論文 前1條

1 鄭寶華;中國(guó)醫(yī)藥制造業(yè)產(chǎn)業(yè)安全及其評(píng)價(jià)研究[D];南京航空航天大學(xué);2010年

相關(guān)碩士學(xué)位論文 前2條

1 王魏云;中醫(yī)藥知識(shí)產(chǎn)權(quán)保護(hù)及品牌戰(zhàn)略研究[D];武漢理工大學(xué);2008年

2 張董;我國(guó)中醫(yī)藥產(chǎn)業(yè)國(guó)際化發(fā)展的知識(shí)產(chǎn)權(quán)問題研究[D];中國(guó)海洋大學(xué);2009年

，

本文編號(hào)：1934996